Get started
Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastETFs

3ZO0 chart


Full chart

3ZO0 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.21 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−9.12 EUR
Net income (FY)
‪−13.62 M‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪1.46 M‬
Beta (1Y)
1.29

Employees


Employees (FY)
4
Change (1Y)
0
Revenue / Employee (1Y)
0.00 EUR
Net income / Employee (1Y)
‪−3.41 M‬ EUR

About Acurx Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David P. Luci
Website
acurxpharma.com
Headquarters
New York
Founded
2017
ISIN
US00510M2035
FIGI
BBG011M00224
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

Check out other big names from the same industry as 3ZO0.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

3ZO0 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Frequently Asked Questions


The current price of 3ZO0 is 3.82 EUR — it has decreased by −7.22% in the past 24 hours. Watch Acurx Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange Acurx Pharmaceuticals, Inc. stocks are traded under the ticker 3ZO0.
3ZO0 stock has risen by 9.76% compared to the previous week, the month change is a −3.23% fall, over the last year Acurx Pharmaceuticals, Inc. has showed a −7.65% decrease.
We've gathered analysts' opinions on Acurx Pharmaceuticals, Inc. future price: according to them, 3ZO0 price has a max estimate of 26.56 EUR and a min estimate of 17.13 EUR. Watch 3ZO0 chart and read a more detailed Acurx Pharmaceuticals, Inc. stock forecast: see what analysts think of Acurx Pharmaceuticals, Inc. and suggest that you do with its stocks.
3ZO0 reached its all-time high on Aug 26, 2025 with the price of 4.76 EUR, and its all-time low was 3.09 EUR and was reached on Sep 5, 2025. View more price dynamics on 3ZO0 chart.
See other stocks reaching their highest and lowest prices.
3ZO0 stock is 18.33% volatile and has beta coefficient of 1.29. Track Acurx Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Acurx Pharmaceuticals, Inc. there?
Today Acurx Pharmaceuticals, Inc. has the market capitalization of ‪6.21 M‬, it has increased by 3.41% over the last week.
Yes, you can track Acurx Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Acurx Pharmaceuticals, Inc. is going to release the next earnings report on Nov 18, 2025. Keep track of upcoming events with our Earnings Calendar.
3ZO0 earnings for the last quarter are −1.60 EUR per share, whereas the estimation was −1.98 EUR resulting in a 19.00% surprise. The estimated earnings for the next quarter are −1.12 EUR per share. See more details about Acurx Pharmaceuticals, Inc. earnings.
Acurx Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
3ZO0 net income for the last quarter is ‪−1.91 M‬ EUR, while the quarter before that showed ‪−1.99 M‬ EUR of net income which accounts for 4.01% change. Track more Acurx Pharmaceuticals, Inc. financial stats to get the full picture.
No, 3ZO0 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 2, 2025, the company has 4 employees. See our rating of the largest employees — is Acurx Pharmaceuticals, Inc. on this list?
Like other stocks, 3ZO0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Acurx Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.